![1]()
News
ENGAGE AF-TIMI: Insulin linked to greater risk for stroke, CV death, bleeding
December 16, 2019
LOS ANGELES – Use of novel oral anticoagulants may be preferred over vitamin K antagonists in patients with diabetes and AFib.
![1]()
News
New heart failure trial data presage guideline revisions
December 9, 2019
PHILADELPHIA – Recent trial findings for sacubitril/valsartan and dapagliflozin in heart failure patients provide a blueprint for guideline changes.
![1]()
News
DAPA-HF: Dapagliflozin benefits regardless of age, HF severity
November 25, 2019
PHILADELPHIA – The SGLT2 inhibitor had similar efficacy in the elderly, and across the spectrum of baseline symptom status.
![1]()
News
Glycemic Control eQUIPS yields success at Dignity Health Sequoia Hospital
November 11, 2019
The tools available in the GC eQUIPS program are powerful for data analysis and benchmarking.
News
New model for CKD risk draws on clinical, demographic factors
November 8, 2019
The equation has demonstrated high discrimination and variable calibration across a range of populations.
News
Dapagliflozin approved for reducing HF hospitalization in diabetes
October 21, 2019
It is the first SGLT2 inhibitor approved in the United States for this indication in adults with type 2 disease.
![1]()
News
Certain diabetes drugs may thwart dementia
October 21, 2019
COPENHAGEN – Intriguing findings from a Danish national registry study.
![1]()
News
FDA adds diabetic kidney disease, heart failure indications to canagliflozin
September 30, 2019
This marks the first time in 20 years that a drug has been indicated for diabetic kidney disease treatment, according to the manufacturer.
News
Machine learning–derived risk score predicts heart failure risk in diabetes patients
September 22, 2019
Highest WATCH-DM scores linked to 5-year heart failure risk approaching 20%.
News
Dapagliflozin meets primary endpoint in the DAPA-HF trial
August 21, 2019
AstraZeneca announces preliminary results in first heart failure trial in an SGLT2 inhibitor.
